Race intensifies to lead next wave of obesity drugs as trial results loom

AI Summary

As new contenders in obesity treatment emerge, key trial results from Pfizer, Viking Therapeutics, and Eli Lilly are anticipated. The competition is heating up as the race to lead the next wave of obesity drugs intensifies.

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly. Published May 18, 2026.